Home
CORT
CORT News

Latest Corcept Therapeutics Incorporated (CORT) News on November 21, 2024

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Zacks

a day ago

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Argus Research

9 days ago

CORT: Rating decreased to a HOLD

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Zacks

10 days ago

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Zacks

13 days ago

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Zacks

13 days ago

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?

Zacks

14 days ago

Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

Zacks

15 days ago

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

3 US Growth Stocks With Insider Ownership As High As 37%

Simply Wall St.

15 days ago

3 US Growth Stocks With Insider Ownership As High As 37%

Argus Research

16 days ago

CORT: Rating increased to a BUY

Here is Why Growth Investors Should Buy Corcept (CORT) Now

Zacks

16 days ago

Here is Why Growth Investors Should Buy Corcept (CORT) Now

Corcept (CORT) Upgraded to Strong Buy: Here's Why

Zacks

16 days ago

Corcept (CORT) Upgraded to Strong Buy: Here's Why

Best Momentum Stocks to Buy for November 5th

Zacks

16 days ago

Best Momentum Stocks to Buy for November 5th

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?

Zacks

16 days ago

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade

Zacks

17 days ago

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

17 days ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?

Zacks

20 days ago

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?

Corcept’s relacorilant GRADIENT trial misses primary endpoint

Clinical Trials Arena

20 days ago

Corcept’s relacorilant GRADIENT trial misses primary endpoint

Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

20 days ago

Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Zacks

21 days ago

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

22 days ago

Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Zacks

22 days ago

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Associated Press Finance

22 days ago

Corcept: Q3 Earnings Snapshot

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Business Wire

22 days ago

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Business Wire

a month ago

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty

Zacks

a month ago

Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty

Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

Zacks

a month ago

Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Zacks

a month ago

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?

Zacks

a month ago

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?

Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks

a month ago

Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?

Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Zacks

a month ago

Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics

Zacks

a month ago

Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics

5 Stocks With Recent Price Strength Amid October Volatility

Zacks

a month ago

5 Stocks With Recent Price Strength Amid October Volatility

Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

Zacks

a month ago

Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Zacks

a month ago

3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Argus Research

a month ago

CORT: Lowering target price to $48.00

3 US Growth Stocks With Insider Ownership And 20% Revenue Growth

Simply Wall St.

a month ago

3 US Growth Stocks With Insider Ownership And 20% Revenue Growth

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?

Simply Wall St.

a month ago

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?

MT Newswires

2 months ago

Corcept Therapeutics Insider Sold Shares Worth $462,800, According to a Recent SEC Filing

Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet

Zacks

2 months ago

Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Zacks

2 months ago

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

Benzinga

2 months ago

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

MT Newswires

2 months ago

Truist Raises Price Target on Corcept Therapeutics to $76 From $65, Keeps Buy Rating

Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?

Insider Monkey

2 months ago

Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Zacks

2 months ago

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

Zacks

2 months ago

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

US Growth Companies With High Insider Ownership

Simply Wall St.

2 months ago

US Growth Companies With High Insider Ownership

Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?

Zacks

2 months ago

Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?

Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors

Simply Wall St.

3 months ago

Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Zacks

3 months ago

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?

Argus Research

3 months ago

CORT: What does Argus have to say about CORT?

Corcept (CORT) Upgraded to Buy: Here's Why

Zacks

3 months ago

Corcept (CORT) Upgraded to Buy: Here's Why

Argus Research

3 months ago

CORT: Raising target price to $36.00

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Zacks

3 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade

Zacks

3 months ago

Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Zacks

3 months ago

5 Small Drug Stocks to Buy as Innovation Reaches Peak

3 US Growth Companies With High Insider Ownership

Simply Wall St.

3 months ago

3 US Growth Companies With High Insider Ownership

Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?

Zacks

4 months ago

Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?

Can Corcept (CORT) Run Higher on Rising Earnings Estimates?

Zacks

4 months ago

Can Corcept (CORT) Run Higher on Rising Earnings Estimates?

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

Zacks

4 months ago

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks

4 months ago

Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?

Corcept Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Corcept Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Zacks

4 months ago

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

Zacks

4 months ago

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

Associated Press Finance

4 months ago

Corcept: Q2 Earnings Snapshot

MT Newswires

4 months ago

Corcept Therapeutics Q2 Net Income, Revenue Rise; 2024 Revenue Guidance Raised

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire

4 months ago

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Argus Research

4 months ago

CORT: Raising target price to $36.00

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

GlobeNewswire

4 months ago

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Navigate Market Turbulence With These 4 Low-Beta Stocks

Zacks

4 months ago

Navigate Market Turbulence With These 4 Low-Beta Stocks

Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics

Zacks

4 months ago

Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics

Argus Research

4 months ago

CORT: Raising target price to $35.00

What Makes Corcept (CORT) a Good Fit for 'Trend Investing'

Zacks

4 months ago

What Makes Corcept (CORT) a Good Fit for 'Trend Investing'

High Insider Ownership Growth Companies On US Exchanges In July 2024

Simply Wall St.

4 months ago

High Insider Ownership Growth Companies On US Exchanges In July 2024

Argus Research

4 months ago

CORT: Lowering target price to $31.00

Argus Research

5 months ago

CORT: Raising target price to $33.00

Corcept (CORT) Shares Rise 20% in Three Months: Here's Why

Zacks

5 months ago

Corcept (CORT) Shares Rise 20% in Three Months: Here's Why

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

GlobeNewswire

5 months ago

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

What Makes Corcept Therapeutics (CORT) a Good Investment Bet?

Insider Monkey

5 months ago

What Makes Corcept Therapeutics (CORT) a Good Investment Bet?

Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks

5 months ago

Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?

MT Newswires

5 months ago

Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym

Teva sues Corcept over mifepristone 'monopoly' for rare disorder

Reuters

5 months ago

Teva sues Corcept over mifepristone 'monopoly' for rare disorder

Insider-Owned Growth Companies To Watch On US Exchanges In June 2024

Simply Wall St.

5 months ago

Insider-Owned Growth Companies To Watch On US Exchanges In June 2024

Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?

Zacks

5 months ago

Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?

Insider Sale: Chief Development Officer William Guyer Sells 10,000 Shares of Corcept ...

GuruFocus.com

6 months ago

Insider Sale: Chief Development Officer William Guyer Sells 10,000 Shares of Corcept ...

MT Newswires

6 months ago

Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

GlobeNewswire

6 months ago

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?

Zacks

6 months ago

Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?

Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ...

GuruFocus.com

6 months ago

Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ...

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

Zacks

6 months ago

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

Zacks

6 months ago

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

MT Newswires

6 months ago

Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

GlobeNewswire

6 months ago

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

MT Newswires

6 months ago

Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing

3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%

Simply Wall St.

6 months ago

3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%

Pipeline Moves: Phase III completion for Corcept’s relaorilant

Clinical Trials Arena

6 months ago

Pipeline Moves: Phase III completion for Corcept’s relaorilant

Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

Zacks

7 months ago

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript

Insider Monkey

7 months ago

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript

MT Newswires

7 months ago

Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating

Share on Social Networks: